Prosecution Insights
Prosecution Insights
12 pending office actions • 2 clients • 10 examiners • 8 art units • 0 of 12 (0%) have an AI response strategy ready • 9 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 12 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 12 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 6 (50%) |
| No statute on record | 6 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HUYNH, PHUONG N | 2 | 65.7% | +53.3% |
| REDDIG, PETER J | 2 | 58.0% | +40.0% |
| HALVORSON, MARK | 1 | 48.0% | +21.6% |
| GRABER, JAMES J | 1 | 46.2% | +56.1% |
| CANELLA, KAREN A | 1 | 62.6% | +32.9% |
| EBBINGHAUS, BRIANA NOEL | 1 | 57.4% | +67.0% |
| CARTER, SANDRA DILLAHUNT | 1 | 55.8% | +29.6% |
| BRISTOL, LYNN ANNE | 1 | 63.7% | +39.7% |
| LU, CHENG | 1 | 54.1% | +67.9% |
| MARTINEZ, TARA L | 1 | 62.7% | +64.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16435257 | TREATMENT OF CANCER USING ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR | BRISTOL, LYNN ANNE | 132d overdue |
| 18351151 | BIOMARKERS PREDICTIVE OF CYTOKINE RELEASE SYNDROME | HALVORSON, MARK | 112d overdue |
| 17161929 | CHO CELL EXPRESSED HET IL-15 | CARTER, SANDRA DILLAHUNT | 86d overdue |
| 18148807 | TREATMENT OF CANCER USING A CD123 CHIMERIC ANTIGEN RECEPTOR | REDDIG, PETER J | 66d overdue |
| 18309370 | CELLS EXPRESSING MULTIPLE CHIMERIC ANTIGEN RECEPTOR (CAR) MOLECULES AND USES THEREFORE | GRABER, JAMES J | 44d overdue |
| 16317943 | TREATMENT AND PREVENTION OF CYTOKINE RELEASE SYNDROME USING A CHIMERIC ANTIGEN RECEPTOR IN COMBINATION WITH A KINASE INHIBITOR | LU, CHENG | 38d overdue |
| 18629314 | COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN DEGRADATION | HUYNH, PHUONG N | 30d overdue |
| 17433812 | MESOPOROUS SILICA PARTICLES COMPOSITIONS FOR VIRAL DELIVERY | EBBINGHAUS, BRIANA NOEL | 30d overdue |
| Client (Assignee) | Pending OAs |
|---|---|
| University of Pennsylvania | 7 |
| Novartis | 5 |
| Art Unit | Apps |
|---|---|
| 1646 | 3 |
| 1641 | 2 |
| 1643 | 2 |
| 1631 | 1 |
| 1632 | 1 |
| 1674 | 1 |
| 1642 | 1 |
| 1654 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18629314 | COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN DEGRADATION | Novartis AG | HUYNH, PHUONG N | 1641 | §103 | Non-Final OA | 30d overdue | Pending | Apr 08, 2024 |
| 18351151 | BIOMARKERS PREDICTIVE OF CYTOKINE RELEASE SYNDROME | The Trustees of the University of Pennsylvania | HALVORSON, MARK | 1646 | §103 | Final Rejection | 112d overdue | Pending | Jul 12, 2023 |
| 18339565 | CD20 THERAPIES, CD22 THERAPIES, AND COMBINATION THERAPIES WITH A CD19 CHIMERIC ANTIGEN RECEPTOR (CAR)-EXPRESSING CELL | The Trustees of the University of Pennsylvania | REDDIG, PETER J | 1646 | Other | Final Rejection | 55d | Pending | Jun 22, 2023 |
| 18309370 | CELLS EXPRESSING MULTIPLE CHIMERIC ANTIGEN RECEPTOR (CAR) MOLECULES AND USES THEREFORE | The Trustees of the University of Pennsylvania | GRABER, JAMES J | 1631 | Other | Final Rejection | 44d overdue | Pending | Apr 28, 2023 |
| 18178886 | SPECIFIC SITES FOR MODIFYING ANTIBODIES TO MAKE IMMUNOCONJUGATES | Novartis AG | HUYNH, PHUONG N | 1641 | Other | Final Rejection | 15d overdue | Pending | Mar 06, 2023 |
| 18148807 | TREATMENT OF CANCER USING A CD123 CHIMERIC ANTIGEN RECEPTOR | The Trustees of the University of Pennsylvania | REDDIG, PETER J | 1646 | Other | Non-Final OA | 66d overdue | Pending | Dec 30, 2022 |
| 18061824 | COMBINATION THERAPIES | Novartis AG | CANELLA, KAREN A | 1643 | §103 | Non-Final OA | 33d | Pending | Dec 05, 2022 |
| 17433812 | MESOPOROUS SILICA PARTICLES COMPOSITIONS FOR VIRAL DELIVERY | Novartis AG | EBBINGHAUS, BRIANA NOEL | 1632 | §103 | Non-Final OA | 30d overdue | Pending | Aug 25, 2021 |
| 17161929 | CHO CELL EXPRESSED HET IL-15 | Novartis AG | CARTER, SANDRA DILLAHUNT | 1674 | §103 | Non-Final OA | 86d overdue | Pending | Jan 29, 2021 |
| 16435257 | TREATMENT OF CANCER USING ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR | The Trustees of the University of Pennsylvania | BRISTOL, LYNN ANNE | 1643 | Other | Final Rejection | 132d overdue | Pending | Jun 07, 2019 |
| 16317943 | TREATMENT AND PREVENTION OF CYTOKINE RELEASE SYNDROME USING A CHIMERIC ANTIGEN RECEPTOR IN COMBINATION WITH A KINASE INHIBITOR | The Trustees of the University of Pennsylvania | LU, CHENG | 1642 | §103 | Final Rejection | 38d overdue | Pending | Jan 15, 2019 |
| 16093758 | COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN EXPRESSION | The Trustees of the University of Pennsylvania | MARTINEZ, TARA L | 1654 | Other | Non-Final OA | 16d overdue | Pending | Oct 15, 2018 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial